PDL Biopharma

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Evofem Biosciences is a biopharmaceutical company based in San Diego, California, focused on addressing unmet needs in women's sexual and reproductive health. The company has developed Phexxi, the first and only hormone-free prescription vaginal gel approved in the United States for pregnancy prevention. In addition to Phexxi, Evofem is also working on EVO100, a vaginal pH regulator aimed at preventing the urogenital transmission of Chlamydia trachomatis and Neisseria gonorrhoeae infections in women. Through its innovative products, Evofem Biosciences aims to enhance reproductive health care options for women.

Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and marketing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture, market, and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used in the treatment of hypertension. By focusing on international markets, Noden Pharma aims to enhance the quality of life for patients through its specialized medical solutions.

Kaleo, Inc. is a pharmaceutical company based in Richmond, Virginia, founded in 2008. It specializes in developing, marketing, and selling combination drug/device products aimed at empowering patients to manage their medical conditions more effectively. Notable products include AUVI-Q, an epinephrine auto-injector designed for infants and small children experiencing severe allergic reactions, and EVZIO, a naloxone HCl injection for opioid overdoses. The company emphasizes drug delivery technology, human factors engineering, and a patient-centric approach to product development, ensuring that its offerings provide clinical and economic benefits. Kaleo distributes its products primarily through distributors in the United States and Canada and was formerly known as Intelliject, Inc., a name it adopted in January 2014.

Paradigm Spine, LLC is a privately-held medical device company specializing in the design and development of innovative solutions for spinal diseases. Headquartered in New York, the company focuses on non-fusion spinal implants and motion-preserving products aimed at treating various spinal disorders. Its notable offerings include the Coflex interspinous implant, which is used for managing facet arthrosis and decompressive procedures, and a minimally invasive pedicle-screw based system known as the DSS system. These products are designed to stabilize the spine while preserving natural anatomical function, catering to the needs of spine specialists globally. Established in 2002 and originally named Spine Motion, LLC, the company rebranded to Paradigm Spine in 2005.

Direct Flow Medical is a medical device company specializing in the development of innovative transcatheter aortic valve replacement systems aimed at treating heart valve diseases. The company's primary focus is on creating a percutaneous aortic tissue valve prosthesis, which offers patients suffering from cardiac valve insufficiency a safe and effective treatment option. With approximately 1.2 million individuals over the age of 65 affected by calcified aortic valves, and only about 150,000 receiving surgical intervention annually, Direct Flow Medical addresses a significant gap in patient care. Their technology allows heart surgeons to conduct repeated assessments of hemodynamic performance prior to final implantation, thereby enhancing patient outcomes and minimizing complications associated with invasive surgeries.

Durata Therapeutics is a biopharmaceutical company dedicated to the development and commercialization of innovative treatments for infectious diseases and acute illnesses. The company's primary focus is on Dalvance, an intravenous antibiotic designed to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria in adults. In addition to Dalvance, Durata is advancing two preclinical antibiotic programs, showcasing its commitment to addressing critical healthcare needs in the field of infectious diseases. The company was established through a collaboration of several venture capital firms to facilitate the late-stage clinical development of its antibiotic candidates.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

LENSAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, established in 2004. It specializes in the design, development, and marketing of advanced femtosecond laser systems aimed at improving cataract surgery outcomes. The company's flagship product, the LENSAR Laser with Streamline IV, enhances the precision and efficiency of refractive cataract surgery by incorporating advanced features such as superior imaging capabilities and customizable treatment planning. This system assists surgeons in managing astigmatism and optimizing refractive results through innovative technology like the proprietary Augmented Reality™ 3-D model and the IntelliAxis Refractive Capsulorhexis® feature. These advancements facilitate accurate toric intraocular lens alignment and streamline surgical workflows, ultimately improving patient outcomes. LENSAR continues to expand its platform's capabilities, enabling the treatment of additional corneal conditions and enhancing the overall surgical experience for both patients and surgeons.

AxoGen, Inc. is a company focused on developing and commercializing innovative solutions for the repair and regeneration of peripheral nerve injuries. Based in Alachua, Florida, and founded in 2002, AxoGen offers a range of products designed for effective surgical procedures, including the AVANCE Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. Additionally, it provides the Axotouch Two-Point Discriminator, a device used to assess the innervation density of skin. AxoGen's offerings are aimed at surgeons and healthcare providers, ensuring clinically and economically effective solutions for nerve repair. The company also has a strategic partnership with the American Tissue Services Foundation for tissue recovery and distributes its products across the United States and several international markets, including Canada, Germany, the United Kingdom, Spain, and South Korea.

ESP Pharma is a hospital-focused pharmaceutical company that specializes in acquiring and enhancing the marketing of approved specialty therapeutics and late-stage development drugs. The company provides innovative therapeutics primarily for high blood pressure, angina, and bone marrow transplants, targeting physicians, hospitals, and acute-care patients. By focusing on specialty pharmaceutical products, ESP Pharma aims to improve the quality of care available to healthcare professionals and enhance patient outcomes in acute-care settings.